Does NINTEDANIB Cause Malignant neoplasm progression? 677 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 677 reports of Malignant neoplasm progression have been filed in association with NINTEDANIB. This represents 2.6% of all adverse event reports for NINTEDANIB.
677
Reports of Malignant neoplasm progression with NINTEDANIB
2.6%
of all NINTEDANIB reports
375
Deaths
129
Hospitalizations
How Dangerous Is Malignant neoplasm progression From NINTEDANIB?
Of the 677 reports, 375 (55.4%) resulted in death, 129 (19.1%) required hospitalization, and 18 (2.7%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for NINTEDANIB. However, 677 reports have been filed with the FAERS database.
What Other Side Effects Does NINTEDANIB Cause?
Diarrhoea (9,103)
Nausea (4,198)
Dyspnoea (3,080)
Decreased appetite (2,832)
Death (2,790)
Weight decreased (2,628)
Vomiting (2,524)
Fatigue (2,511)
Cough (2,193)
Idiopathic pulmonary fibrosis (1,905)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which NINTEDANIB Alternatives Have Lower Malignant neoplasm progression Risk?
NINTEDANIB vs NINTEDANIB ESYLATE
NINTEDANIB vs NIRAPARIB
NINTEDANIB vs NIRMATRELVIR\RITONAVIR
NINTEDANIB vs NIROGACESTAT
NINTEDANIB vs NIROGACESTAT HYDROBROMIDE